IV Ketamine Infusion Therapy for Treatment-Resistant Depression: What a Harvard Study Reveals
IV ketamine infusion therapy for treatment-resistant depression is gaining attention as a powerful alternative when traditional antidepressants have not provided relief. A groundbreaking study from Harvard Medical School and McLean Hospital directly compared IV ketamine infusions to intranasal esketamine in patients with severe depression who had exhausted standard treatment options. The study found that IV ketamine produced stronger symptom reduction and earlier improvement, supporting its emerging role as an evidence-based therapeutic option.
Key Findings from the Harvard Ketamine Study
The study followed 153 adults with severe depression who had not improved with traditional antidepressants.
Participants received either IV ketamine infusions or intranasal esketamine over four to five weeks.
By the end of the study:
- IV ketamine led to a 49% reduction in depression symptoms
- Intranasal esketamine led to a 39% reduction
- IV patients often showed improvement after their first session, while intranasal patients typically needed several treatments to feel results
Read the full Harvard Gazette article here:
First study to compare two ketamine therapies for patients with severe depression
https://news.harvard.edu/gazette/story/2025/09/first-study-to-compare-two-ketamine-therapies-for-patients-with-severe-depression/
Why IV Ketamine Infusion Therapy Is Getting Attention
IV ketaIV ketamine works differently from traditional antidepressants. Rather than primarily targeting serotonin or other monoamine systems, ketamine acts on the brain’s glutamate system, including NMDA receptor signaling. Researchers continue to study how these effects may contribute to changes in depressive symptoms.
One reason IV ketamine has received significant attention is the speed of response observed in some patients with treatment-resistant depression. In the Harvard-affiliated study, improvement was observed earlier among patients receiving IV ketamine, and the IV group experienced a greater overall reduction in depression severity scores during the treatment period.
IV administration also allows ketamine to be delivered directly into the bloodstream in a controlled medical setting, where dosing and the patient’s response can be carefully monitored.
These findings add to a growing body of research surrounding IV ketamine as a potential option for appropriately selected patients with treatment-resistant depression.
Physician-Led IV Ketamine Therapy at WOW Spine
At WOW Spine, patient safety is our highest priority. Every ketamine infusion is administered under medical supervision in a setting that meets the standards of an ambulatory surgery anesthesia site of service.
Our infusion environment includes:
- Continuous heart rate, blood pressure, and oxygen monitoring
- Staff trained in anesthesia and sedation safety
- Clear emergency protocols and readiness systems
- A designated recovery space with established discharge criteria and follow-up monitoring
- Physician oversight by Dr. Mike Martinez, a double board-certified Anesthesiologist and Interventional Spine & Pain Management Specialist
Dr. Martinez’s background in anesthesiology and pain medicine brings specialized experience in IV medication administration, physiological monitoring, and ketamine therapy.
For patients considering IV ketamine, who evaluates you, administers your treatment, and monitors your response matters just as much as the medication itself.
Learn more about our IV Ketamine Infusion Therapy or contact WOW Spine to discuss whether treatment may be appropriate for you.
